Internal Medicine, Nephrology · Riverside, CA
NPI
1396285698
Since 2017
Specialty
Internal Medicine, Nephrology
Code 207RN0300X
Group practices
1
Medicare group memberships
Hospitals
0
Hospital affiliations
9939 Magnolia Ave
Riverside, CA, 92503
Phone (855) 745-8600
Groups this clinician bills Medicare through
Medicare paid, 2024
$29K
349 services
Medicare patients, 2024
81
Average age 76
Drug cost, 2024
$1.5M
3,965 prescriptions
Company payments, 2025
$567
From 12 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Akpobo Akporotu was code 36415 (venipuncture blood collection), 130 times for 46 patients. In total Akpobo Akporotu billed 349 services in 10 codes, and Medicare paid $29K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2022-11-18.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 36415 Venipuncture Blood Collection | Office | 130 | 46 | $8.65 | $1,125 |
| 99215 Office E&M - Established | Office | 85 | 46 | $138.09 | $12K |
| 99214 Office E&M - Established | Office | 68 | 41 | $93.99 | $6,391 |
| 99205 Office E&M - New | Office | 31 | 31 | $165.23 | $5,122 |
| 99204 Office E&M - New | Office | 12 | 12 | $113.62 | $1,363 |
By year: 2023 $17K for 165 services; 2024 $29K for 349 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 130 | 46 | $8.65 | $1,125 |
Medicare prescription drug claims, 2024
In 2024, the drug Akpobo Akporotu prescribed most often to Medicare patients was Farxiga (Dapagliflozin Propanediol), with 726 prescriptions and refills. In total Akpobo Akporotu wrote 3,965 Medicare prescriptions that cost $1.5M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Farxiga Dapagliflozin Propanediol | 726 | 948 | 174 | $496K |
| Dapagliflozin Dapagliflozin Propanediol | 436 | 468 | 109 | $230K |
| Nifedipine Er Nifedipine | 361 | 735 | 113 | $9,935 |
| Kerendia Finerenone | 358 | 413 | 75 | $250K |
| Lisinopril Generic | 225 | 533 | 104 | $2,446 |
| Rayaldee Calcifediol | 207 | 216 | 52 | $244K |
| Atorvastatin Calcium Generic | 194 | 447 | 96 | $3,074 |
| Jardiance Empagliflozin | 121 | 187 | 45 | $103K |
| Metformin Hcl Generic | 104 | 170 | 47 | $774 |
| Lokelma Sodium Zirconium Cyclosilicate | 87 | 89 | 26 | $66K |
| Losartan Potassium Generic | 78 | 195 | 36 | $1,235 |
| Ciprofloxacin Hcl Generic | 78 | 78 | 63 | $173 |
| Famotidine Generic | 68 | 113 | 33 | $665 |
| Hydrochlorothiazide Generic | 67 | 180 | 38 | $566 |
| Glipizide Generic | 61 | 108 | 28 | $454 |
Brand drugs: 2,058 claims; generic drugs: 1,895 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Akpobo Akporotu $567 ($567 in general payments such as food, travel and fees) from 12 companies. The largest payer was Otsuka Pharmaceutical Development & Commercialization, Inc. with $86.01.
| Company | Payments | Amount |
|---|---|---|
| Otsuka Pharmaceutical Development & Commercialization, Inc. 4578.T | 2 | $86.01 |
| Akebia Therapeutics Inc AKBA | 3 | $71.73 |
| OPKO Pharmaceuticals, LLC | 4 | $68.84 |
| AstraZeneca Pharmaceuticals LP AZN | 3 | $63.73 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 3 | $61.64 |
| Novo Nordisk Inc NVO | 2 | $50.53 |
| Apellis Pharmaceuticals, Inc. APLS | 2 | $44.05 |
| Calliditas Therapeutics US Inc. | 1 | $33.36 |
| Bayer Healthcare Pharmaceuticals Inc. BAYN.DE | 1 | $23.86 |
| Vifor Pharma, Inc. | 1 | $22.29 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.